ATE348814T1 - Verfahren zur herstellung von chinolinderivaten - Google Patents
Verfahren zur herstellung von chinolinderivatenInfo
- Publication number
- ATE348814T1 ATE348814T1 AT03725956T AT03725956T ATE348814T1 AT E348814 T1 ATE348814 T1 AT E348814T1 AT 03725956 T AT03725956 T AT 03725956T AT 03725956 T AT03725956 T AT 03725956T AT E348814 T1 ATE348814 T1 AT E348814T1
- Authority
- AT
- Austria
- Prior art keywords
- quinoline derivatives
- formula
- producing quinoline
- producing
- chaineded
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000001924 cycloalkanes Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201778A SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Process for the manufacture of quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE348814T1 true ATE348814T1 (de) | 2007-01-15 |
Family
ID=20288148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03725956T ATE348814T1 (de) | 2002-06-12 | 2003-05-14 | Verfahren zur herstellung von chinolinderivaten |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1511732B9 (de) |
| JP (1) | JP4584709B2 (de) |
| KR (1) | KR100979216B1 (de) |
| CN (1) | CN100418950C (de) |
| AT (1) | ATE348814T1 (de) |
| AU (1) | AU2003228195B2 (de) |
| BR (1) | BR0311674A (de) |
| CA (1) | CA2487329C (de) |
| CY (1) | CY1107555T1 (de) |
| DE (1) | DE60310554T2 (de) |
| DK (1) | DK1511732T5 (de) |
| ES (1) | ES2278160T3 (de) |
| HR (1) | HRP20050028B1 (de) |
| IL (1) | IL165155A (de) |
| IS (1) | IS2975B (de) |
| ME (1) | ME00435B (de) |
| MX (1) | MXPA04012276A (de) |
| NO (1) | NO329162B1 (de) |
| NZ (1) | NZ536768A (de) |
| PL (1) | PL210259B1 (de) |
| PT (1) | PT1511732E (de) |
| RS (1) | RS51021B (de) |
| RU (1) | RU2291861C2 (de) |
| SE (1) | SE0201778D0 (de) |
| SI (1) | SI1511732T1 (de) |
| UA (1) | UA78310C2 (de) |
| WO (1) | WO2003106424A1 (de) |
| ZA (1) | ZA200409430B (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| CA2670966A1 (en) | 2006-11-28 | 2008-06-05 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| ME02414B (de) | 2009-07-30 | 2016-09-20 | Teva Pharma | Behandlung von morbus crohn mit laquinimod |
| PT2467372T (pt) | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| CN102791130B (zh) | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| JP5819328B2 (ja) | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
| SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP3056205A1 (de) * | 2010-07-09 | 2016-08-17 | Teva Pharmaceutical Industries, Ltd. | 5-chlor-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydrochinolin-3-carboxamid, salze und verwendungen davon |
| PT2590949E (pt) * | 2010-07-09 | 2016-03-07 | Active Biotech Ab | Método para o fabrico de quinolina-3-carboxamidas |
| EP2537517A1 (de) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
| CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| US9956212B2 (en) | 2014-09-23 | 2018-05-01 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| JP6715833B2 (ja) | 2014-11-19 | 2020-07-01 | アクティブ バイオテック エイビー | 白血病の治療に使用するためのキノリンカルボキサミド |
| IL295780A (en) | 2020-03-03 | 2022-10-01 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN111732540B (zh) * | 2020-07-20 | 2020-11-13 | 湖南速博生物技术有限公司 | 一种罗喹美克的制备方法 |
| AU2021313388A1 (en) | 2020-07-23 | 2023-01-19 | Erasmus University Medical Center Rotterdam (Erasmus Mc) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| KR20230133317A (ko) | 2021-01-18 | 2023-09-19 | 액티브 바이오테크 에이비 | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 |
| KR20240012436A (ko) | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
-
2002
- 2002-06-12 SE SE0201778A patent/SE0201778D0/xx unknown
-
2003
- 2003-05-14 CN CNB038135310A patent/CN100418950C/zh not_active Expired - Lifetime
- 2003-05-14 JP JP2004513257A patent/JP4584709B2/ja not_active Expired - Lifetime
- 2003-05-14 ME MEP-2008-656A patent/ME00435B/me unknown
- 2003-05-14 EP EP03725956A patent/EP1511732B9/de not_active Expired - Lifetime
- 2003-05-14 DE DE60310554T patent/DE60310554T2/de not_active Expired - Lifetime
- 2003-05-14 UA UA20041109639A patent/UA78310C2/xx unknown
- 2003-05-14 BR BRPI0311674-3A patent/BR0311674A/pt not_active Application Discontinuation
- 2003-05-14 PT PT03725956T patent/PT1511732E/pt unknown
- 2003-05-14 WO PCT/SE2003/000780 patent/WO2003106424A1/en not_active Ceased
- 2003-05-14 SI SI200330688T patent/SI1511732T1/sl unknown
- 2003-05-14 MX MXPA04012276A patent/MXPA04012276A/es active IP Right Grant
- 2003-05-14 HR HRP20050028AA patent/HRP20050028B1/hr not_active IP Right Cessation
- 2003-05-14 AU AU2003228195A patent/AU2003228195B2/en not_active Expired
- 2003-05-14 PL PL373817A patent/PL210259B1/pl unknown
- 2003-05-14 KR KR1020047020088A patent/KR100979216B1/ko not_active Expired - Lifetime
- 2003-05-14 NZ NZ536768A patent/NZ536768A/en not_active IP Right Cessation
- 2003-05-14 ES ES03725956T patent/ES2278160T3/es not_active Expired - Lifetime
- 2003-05-14 DK DK03725956T patent/DK1511732T5/da active
- 2003-05-14 CA CA2487329A patent/CA2487329C/en not_active Expired - Lifetime
- 2003-05-14 AT AT03725956T patent/ATE348814T1/de active
- 2003-05-14 RU RU2005100054/04A patent/RU2291861C2/ru not_active IP Right Cessation
- 2003-05-14 RS YUP-1076/04A patent/RS51021B/sr unknown
-
2004
- 2004-11-11 IL IL165155A patent/IL165155A/en active IP Right Grant
- 2004-11-23 ZA ZA200409430A patent/ZA200409430B/xx unknown
- 2004-11-24 IS IS7550A patent/IS2975B/is unknown
- 2004-12-29 NO NO20045703A patent/NO329162B1/no not_active IP Right Cessation
-
2007
- 2007-03-01 CY CY20071100295T patent/CY1107555T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE348814T1 (de) | Verfahren zur herstellung von chinolinderivaten | |
| ATE533775T1 (de) | Verfahren zur herstellung von 17-vinyl-triflaten als intermediate | |
| PE20050077A1 (es) | Derivados de 4-pirrolidino-fenil-bencil-eter | |
| DE602004019329D1 (de) | Verfahren zur herstellung substituierter nikotinsäureester | |
| ATE370131T1 (de) | Verfahren zur herstellung von 5-(1,3-oxazol-2- yl)benzoesäurederivaten | |
| DE502004004970D1 (de) | Verfahren zur herstellung von oh-geschützten ä4-(2,6-diamino-9h-purin-9-yl)-1,3-dioxolan-2-ylümethanol-derivaten | |
| ATE501120T1 (de) | Verfahren zur herstellung von isoindolderivaten | |
| ATE521594T1 (de) | Verfahren zur herstellung von chinolin-3- carbonsäureverbindungen | |
| DE502004010100D1 (de) | Verfahren zur Herstellung von 9,10-Dihydro-9-oxa-10-organyl-oxyphosphaphenanthren-10-oxid oder -thion und an den Phenylgruppen substituierten Derivativen desselben | |
| ATE419230T1 (de) | Verfahren zur herstellung von 2,6-dihalo-para- trifluoromethylanilin | |
| DE60104704D1 (de) | Verfahren zur herstellung einer substituierten imidazopyridinverbindung | |
| ATE244706T1 (de) | Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung | |
| ATE390400T1 (de) | Verfahren zur herstellung von alpha'-chlorketonen | |
| ATE423096T1 (de) | Verfahren zur herstellung von 2- azabicycloä3.3.0üoctan-3-carbonsäurederivaten | |
| ATE402940T1 (de) | Verfahren zur herstellung von 3-cephem- verbindungen | |
| DE602004030091D1 (de) | Verfahren zur reduktiven deshalogenierung | |
| DE60303023D1 (de) | Halb-synthetisches verfahren für die herstellung von n-debenzoylpaclitaxel | |
| DE602004032089D1 (de) | Verfahren zur Herstellung von 1-Methylindazol-3-Carbonsäure | |
| TR200200307T2 (tr) | Alfa-Kloroepoksi esterleri vasıtasıyla asit hazırlama prosesi | |
| ATE227735T1 (de) | Verfahren zur herstellung von 4,4- dimethyl - 3beta- hydroxypregna -8,14-dien-21- carbonsäureestern und zwischenprodukte im verfahren | |
| DE502004012114D1 (de) | Verfahren zur herstellung von cyclischen n-substituierten alpha-iminocarbons uren | |
| DE60128336D1 (de) | Eine zwischenverbindung und verfahren zu deren herstellung | |
| DE60306506D1 (de) | Verfahren | |
| ATE253048T1 (de) | Verfahren zur herstellung von piperidincarbonsäureamiden | |
| ATE405563T1 (de) | Verfahren zur herstellung von n-substituierten 3beta-aminonortropanen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1511732 Country of ref document: EP |